Other
Residual blood
Residual blood is an intervention with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Other(1)
Detailed Status
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Trials by Status
completed150%
unknown150%
Recent Activity
0 active trials
Showing 2 of 2
unknown
Population PK of Antibiotics, Sedative and Analgesics, and Antiplatelet Drugs During ECMO
NCT05406492
completed
Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)
NCT02581280
Clinical Trials (2)
Showing 2 of 2 trials
NCT05406492
Population PK of Antibiotics, Sedative and Analgesics, and Antiplatelet Drugs During ECMO
NCT02581280
Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)
All 2 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 2